NAMVONA Trademark

Trademark Overview

On Thursday, April 11, 2019, a trademark application was filed for NAMVONA with the United States Patent and Trademark Office. The USPTO has given the NAMVONA trademark a serial number of 88381582. The federal status of this trademark filing is REGISTERED as of Tuesday, May 26, 2020. This trademark is owned by Glaxo Group Limited. The NAMVONA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
namvona

General Information

Serial Number88381582
Word MarkNAMVONA
Filing DateThursday, April 11, 2019
Status700 - REGISTERED
Status DateTuesday, May 26, 2020
Registration Number6061830
Registration DateTuesday, May 26, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 10, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 1, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB

Trademark Events

Event DateEvent Description
Friday, October 6, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 6, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 6, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 6, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 6, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, November 8, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 8, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, November 8, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 26, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, March 10, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 10, 2020PUBLISHED FOR OPPOSITION
Wednesday, February 19, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, February 3, 2020NOA CANCELLED; REPUBLICATION REQUIRED
Monday, February 3, 2020NOTICE OF ALLOWANCE CANCELLED
Friday, January 31, 2020PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Thursday, January 30, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 28, 2020SOU EXTENSION 1 GRANTED
Tuesday, January 28, 2020SOU EXTENSION 1 FILED
Tuesday, January 28, 2020SOU TEAS EXTENSION RECEIVED
Friday, December 6, 2019TEAS RESPONSE TO PETITION INQUIRY LETTER
Wednesday, December 4, 2019PETITION INQUIRY LETTER ISSUED
Tuesday, December 3, 2019ASSIGNED TO PETITION STAFF
Tuesday, October 1, 201944(e) PETITION - RECEIVED
Tuesday, December 3, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, November 14, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, October 1, 2019TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, September 17, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 23, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 23, 2019PUBLISHED FOR OPPOSITION
Wednesday, July 3, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, June 15, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, June 10, 2019ASSIGNED TO EXAMINER
Wednesday, May 1, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 15, 2019NEW APPLICATION ENTERED

Related Keywords

namvona pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological